Skip to main content

Desmopressin

Desmopressin (DDAVP) is a synthetic vasopressin V2-receptor agonist with three established urologic uses: (1) nocturia from nocturnal polyuria in adults — its principal indication; (2) primary monosymptomatic nocturnal enuresis in children; and (3) perioperative hemostasis in patients with mild hemophilia A or von Willebrand disease Type I undergoing urologic surgery. It is the only antidiuretic agent specifically indicated for nocturia due to nocturnal polyuria, but use is gated by the risk of hyponatremia — a class effect that carries an FDA boxed warning and a 13-fold higher rate than comparator OAB drugs in population data.[1][2][3][4]

For the broader nocturia evaluation framework, see Nocturia. For the storage-OAB pharmacology landing, see Storage / OAB.

Pharmacology​

Mechanism​

Desmopressin is a modified vasopressin analogue (deaminated cysteine-1, D-arginine-8) that yields:[5]

  • Selective V2 agonism in the renal collecting duct → aquaporin-2 trafficking to the apical membrane → free-water reabsorption → reduced urine production
  • Markedly decreased V1 (vascular) activity — clinically antidiuretic doses are below the vasopressor threshold
  • Hemostatic effect — releases stored factor VIII and von Willebrand factor (vWF) from endothelial Weibel–Palade bodies, raising factor VIII activity 300–400% within 30–90 min and lasting 8–12 h
  • Prolonged duration vs native AVP — antidiuretic half-life ~2–3 h; hemostatic effect 8–12 h

Pharmacokinetics by formulation​

FormulationOnsetNotes
Oral tabletAntidiuretic onset ~1 h; peak 4–7 hBioavailability 0.08–0.16%
Orally disintegrating tablet (ODT, Nocdurna)Sublingual absorptionNot affected by nasal congestion or GI transit; no fluid intake required[7]
Intranasal sprayPeak ~1.5 hProlonged half-life → higher hyponatremia risk; intranasal is no longer approved for enuresis[8]
IV / SC injectionMinutesHemostasis and central DI; ~1/10th the intranasal maintenance dose[3]

Formulations and dose equivalence​

FormulationBrandsDose rangePrimary urologic indication
Oral tabletGeneric, DDAVP0.1–0.6 mgCDI, primary nocturnal enuresis, off-label nocturia
ODT (Nocdurna)25 µg (women) / 50 µg (men)25–50 µg SL qhsNocturia due to NP (FDA-approved)[2][3]
Low-dose intranasal (Noctiva)1.66 µg (women) / 2.49 µg (men)per doseNocturia due to NP in adults with ≥ 2 voids/night[3]
Standard intranasal (DDAVP NS)10–40 µgCDI; not approved for enuresis
IV / SCDDAVP Injection0.3 µg/kg IV (max 20 µg)Hemophilia A, vWD Type I, CDI[5][6]

Urologic Applications​

1. Nocturia from nocturnal polyuria (adults)​

The dominant urologic use. Nocturnal polyuria — defined as nocturnal urine production exceeding 20–33% of 24-hour output (age-dependent) — is the major contributor in most nocturia and frequently reflects insufficient nocturnal AVP secretion, making desmopressin a pathophysiology-directed treatment.[1]

Efficacy.

  • A Cochrane review of 14 RCTs (2,966 men) found desmopressin reduces nocturnal voids by 0.46–0.85 per night vs placebo, with the larger effect at 3–12 months (MD −0.85, 95% CI −1.17 to −0.53).[9]
  • A systematic review of 10 RCTs (2,191 patients) found a 100 µg dose provided ~1 additional hour of undisturbed sleep before the first void and 0.72 fewer voids per night vs placebo.[10]
  • Effect size is larger in patients with documented NP and at higher oral doses.[4][9]
  • Desmopressin has a similar effect on nocturnal voids as alpha-blockers (MD 0.30, 95% CI −0.20 to 0.80; moderate quality), and adding desmopressin to an alpha-blocker yields only a small, likely unimportant additional reduction.[9]
  • Real-world data in older men (60–95 yr) starting at 0.1 mg oral showed reductions of 2–3 voids/night, 660–705 mL in nocturnal urine volume, and 1–2 h more undisturbed sleep; 70.1% completed 3 months and 16.7% discontinued for hyponatremia detected on monitoring.[11]

Sex-specific dosing (FDA-approved Nocdurna ODT):

PatientDose
Women25 µg SL at bedtime
Men50 µg SL at bedtime

Women have higher serum desmopressin concentrations and greater hyponatremia risk at equivalent doses — the rationale for sex-stratified dosing.[2][3]

Older adults. The AGS Beers Criteria (2023) recommends avoiding desmopressin for nocturia / NP in older adults due to hyponatremia risk, favoring behavioral interventions (the "SCREeN" approach: Sleep, Cardiovascular, Renal, Endocrine, Neurological) and alternative pharmacotherapy (β3-agonists, alpha-blockers) instead.[12] When desmopressin is used in this population, start at the lowest available oral dose (0.1 mg) with frequent sodium monitoring.[11]

2. Primary monosymptomatic nocturnal enuresis (children ≥ 6 yr)​

Desmopressin is one of the two first-line treatments (the other being enuresis alarms).[8][13]

Efficacy.[13]

  • 1.34 fewer wet nights per week vs placebo (95% CI 1.11–1.57)
  • Lower failure rate to achieve 14 consecutive dry nights (RR 0.84)
  • Higher relapse rate than enuresis alarms (65% vs 46%; RR 1.42) — alarms produce more durable cure
  • Combining desmopressin with an enuresis alarm achieves 0.88 fewer wet nights/week vs desmopressin alone

Dosing. Oral tablet 0.2 mg at bedtime → titrate to 0.4–0.6 mg; ODT 120 µg → 360 µg.[6][7]

Practical points.[7][8]

  • Take 1 hour before the last void before bed
  • Restrict fluids from 1 h before to 8 h after dosing
  • Effective only on the night of administration — daily use for continuous effect; can be used as-needed for sleepovers / camp
  • Discontinue if no improvement after 1–2 weeks; if effective, continue 3 months then trial a drug holiday
  • Intranasal is no longer approved for enuresis due to high hyponatremia risk
  • The most common cause of unresponsiveness is reduced nocturnal bladder capacity, not polyuria

The International Consultation on Incontinence assigns desmopressin a Level 1, Grade A recommendation in monosymptomatic enuresis.[7]

3. Neurogenic LUTD nocturia and frequency​

Desmopressin has an established role for nocturia and urinary frequency in neurological populations:[14][15]

  • Multiple sclerosis — most studied population; symptom relief for 6 h[14][15]
  • Parkinson's disease — useful for autonomic-dysfunction-related NP[14]
  • Spinal cord injury — patients lose normal diurnal AVP variation, producing NP; desmopressin reduces nocturnal output (small studies)[15][16]
  • Other: multiple system atrophy, stroke, neural tube defects[15]

A meta-analysis of 14 studies (200 patients, mostly MS) found significantly fewer nocturnal voids (MD −0.75, 95% CI −1.10 to −0.41).[15]

Caveats: dose no more than once in 24 hours; particular caution in age > 65 or dependent leg edema (CHF / hyponatremia risk).[14]

4. Perioperative hemostasis in urologic surgery​

FDA-approved for hemostasis in mild hemophilia A (factor VIII > 5%) and mild-to-moderate vWD Type I (factor VIII > 5%) during surgery.[3][5]

Dose. 0.3 µg/kg IV (max 20 µg) over 15–30 min, given 30 min before the procedure; may repeat at 8–12 h and once daily thereafter.[3]

Tachyphylaxis. Occurs with administration more often than every 48 h; the response is reproducible if given every 2–3 days.[5]

Urologic relevance.

  • Useful for known mild bleeding disorders undergoing TURP, prostatectomy, cystoscopy with biopsy, or other urologic procedures[3][17]
  • ASA Practice Guidelines for Perioperative Blood Management note placebo-controlled meta-analytic evidence that desmopressin reduces postoperative blood loss (Category A1-B)[17]
  • Not indicated for severe vWD Type I, Type 2B, Type 2N, Type 3, or factor VIII–antibody patients[3]
  • Not standard for routine post-TURP hematuria in patients without bleeding disorders — tranexamic acid is the preferred pharmacologic hemostatic agent[18]

5. Central diabetes insipidus​

Urologists may encounter transient central DI after transsphenoidal pituitary surgery or head trauma — massive polyuria with polydipsia.[6][19][20]

RouteDose
OralStart 0.05 mg BID; range 0.1–1.2 mg/day in divided doses
IV / SC2–4 µg/day in 1–2 doses
Intranasal10–40 µg/day

Adjust to urine volume and osmolality; titrate morning and evening doses separately to preserve diurnal rhythm. Ineffective for nephrogenic DI.[6]

Hyponatremia — the dose-limiting safety concern​

The defining toxicity, with an FDA boxed warning on every formulation.[3][5]

Epidemiology​

  • A population-based cohort study reported a hyponatremia rate of 146 per 1,000 person-years with desmopressin vs 11 per 1,000 with oxybutynin — a 13-fold higher rate (HR 13.19; 95% CI 6.69–26.01); at 30 days the rate was 19-fold higher (HR 19.41).[21]
  • In the real-world older-male cohort, 16.7% discontinued for hyponatremia detected on routine monitoring.[11]
  • Hyponatremia (RR 5.1) and headache (RR 4.3) are the most common adverse events in meta-analysis.[10]

Risk factors[21][22]​

  • Age ≥ 65 years — the dominant risk factor
  • Extremes of age (pediatric and geriatric)
  • Intranasal formulations (longer half-life)
  • Concurrent diuretic use (especially loop diuretics)
  • Systemic or inhaled glucocorticoids
  • Polydipsia / excessive fluid intake
  • CHF, CKD, SIADH, cystic fibrosis
  • Intercurrent illness with fluid shifts (GI illness)

Contraindications (FDA label)[3][5]​

  • Hyponatremia or history of hyponatremia
  • Excessive fluid intake / polydipsia
  • Loop diuretics or systemic / inhaled glucocorticoids
  • Known or suspected SIADH
  • Conditions that cause fluid or electrolyte imbalance
  • Moderate-to-severe renal impairment (eGFR < 50 mL/min)

Required monitoring (Nocdurna and Noctiva)[3][5]​

  1. Confirm normal serum sodium before starting or resuming
  2. Recheck within 7 days of initiation
  3. Recheck at ~ 1 month
  4. Periodic monitoring thereafter
  5. More frequent monitoring in patients ≥ 65 or with risk factors
  6. Hold or stop if hyponatremia occurs

Patient counseling — symptoms of water intoxication[6]​

Headache, nausea / vomiting, weight gain, fatigue, lethargy, disorientation, muscle weakness or cramps, irritability, decreased appetite, restlessness. Severe: seizure, coma, respiratory arrest. Discontinue and call if these develop.

Fluid restriction[6][7]​

Limit intake from 1 h before through 8 h after dosing. For enuresis: no drinking 2 h before bedtime or for the rest of the night.

Other Adverse Effects​

  • Headache (RR 4.3 vs placebo)[10]
  • Slight BP elevation (rare with oral; more common with intranasal / IV at high doses)
  • Facial flushing (with IV)
  • Nausea, abdominal cramps
  • Rare anaphylaxis (IV and intranasal; not reported with oral)
  • Theoretical thrombotic risk from factor VIII elevation

Drug Interactions[22]​

  • Loop diuretics, thiazides — increase hyponatremia risk (loop diuretics are a contraindication for nocturia formulations)
  • SSRIs, SNRIs, TCAs — may potentiate hyponatremia via SIADH
  • NSAIDs — may potentiate antidiuretic effect
  • Carbamazepine, chlorpromazine — may enhance antidiuretic effect
  • Glucocorticoids (systemic / inhaled) — contraindicated with nocturia formulations

Practical Prescribing Summary​

IndicationFormulationDoseMonitoring
Nocturia (NP) — womenNocdurna ODT25 µg SL qhsNa⁺ at baseline, 7 d, 1 mo, then periodic
Nocturia (NP) — menNocdurna ODT50 µg SL qhsSame
Nocturia — older menOral tabletStart 0.1 mg qhsNa⁺ at 1, 2, 3 mo; hold if Na⁺ ≤ 135
Nocturnal enuresis (≥ 6 yr)Oral tablet or ODT0.2 mg → 0.6 mg (tab) or 120 → 360 µg (ODT) qhsNa⁺ if symptoms; mandatory fluid restriction
Neurogenic nocturia (MS, PD, SCI)Oral or intranasal0.1–0.2 mg PO; 10–20 µg INNa⁺ monitoring; ≤ 1×/day; caution > 65 yr or leg edema
Perioperative hemostasisIV0.3 µg/kg (max 20 µg) over 15–30 min, 30 min pre-opFactor VIII, Na⁺; tachyphylaxis if < 48 h interval
Central DIOral / IN / IV-SC0.05–0.8 mg PO; 2–4 µg IV-SC; 10–40 µg INUrine volume, osmolality, Na⁺

Clinical Positioning​

  • Document nocturnal polyuria with a bladder diary (≥ 33% of 24-h output overnight, or age-adjusted threshold) before starting — not every "nocturia" patient has NP, and patients without NP are better treated with antimuscarinics, β3-agonists, or BPH-directed therapy
  • First-line behavioral measures — fluid restriction in the evening, leg elevation, compression stockings for dependent edema, address apnea and CHF
  • Add desmopressin when behavioral measures are inadequate and NP is confirmed
  • Older adults — Beers Criteria recommend avoidance; if used, start lowest dose with rigorous sodium monitoring
  • Hyponatremia is not optional — baseline plus 7-day plus 1-month plus periodic sodium monitoring is the standard; this is not a set-and-forget medication

See Also​

References​

1. Weiss JP, Everaert K. "Management of nocturia and nocturnal polyuria." Urology. 2019;133S:24–33. doi:10.1016/j.urology.2019.09.022

2. Chung E. "Desmopressin and nocturnal voiding dysfunction: clinical evidence and safety profile in the treatment of nocturia." Expert Opin Pharmacother. 2018;19(3):291–298. doi:10.1080/14656566.2018.1429406

3. US Food and Drug Administration. Desmopressin Acetate — prescribing information. Updated 2025-10-23.

4. Han J, Jung JH, Bakker CJ, Ebell MH, Dahm P. "Desmopressin for treating nocturia in men." Cochrane Database Syst Rev. 2017;10:CD012059. doi:10.1002/14651858.CD012059.pub2

5. US Food and Drug Administration. Desmopressin Acetate — prescribing information. Updated 2022-10-12.

6. US Food and Drug Administration. Desmopressin Acetate — prescribing information. Updated 2024-12-06.

7. Vande Walle J, Rittig S, Bauer S, et al. "Practical consensus guidelines for the management of enuresis." Eur J Pediatr. 2012;171(6):971–983. doi:10.1007/s00431-012-1687-7

8. Robson WL. "Evaluation and management of enuresis." N Engl J Med. 2009;360(14):1429–1436. doi:10.1056/NEJMcp0808009

9. Han J, Jung JH, Bakker CJ, Ebell MH, Dahm P. "Desmopressin for treating nocturia in men." BJU Int. 2018;122(4):549–559. doi:10.1111/bju.14183

10. Ebell MH, Radke T, Gardner J. "A systematic review of the efficacy and safety of desmopressin for nocturia in adults." J Urol. 2014;192(3):829–835. doi:10.1016/j.juro.2014.03.095

11. Chu C, Lin CC. "Real-world safety and effectiveness of an initial 0.1 mg dose of desmopressin in older men with nocturnal polyuria." J Urol. 2026. doi:10.1097/JU.0000000000005003

12. Steinman MA. "Alternative treatments to selected medications in the 2023 American Geriatrics Society Beers Criteria®." J Am Geriatr Soc. 2025;73(9):2657–2677. doi:10.1111/jgs.19500

13. Lauters RA, Garcia KW, Arnold JJ. "Enuresis in children: common questions and answers." Am Fam Physician. 2022;106(5):549–556.

14. Panicker JN, Fowler CJ, Kessler TM. "Lower urinary tract dysfunction in the neurological patient: clinical assessment and management." Lancet Neurol. 2015;14(7):720–732. doi:10.1016/S1474-4422(15)00070-8

15. Hajebrahimi S, Darvishi A, HajEbrahimi R, et al. "Efficacy and safety of desmopressin in nocturia and nocturnal polyuria control of neurological patients: a systematic review and meta-analysis." Neurourol Urodyn. 2024;43(1):167–182. doi:10.1002/nau.25291

16. Kilinç S, Akman MN, Levendoglu F, Ozker R. "Diurnal variation of antidiuretic hormone and urinary output in spinal cord injury." Spinal Cord. 1999;37(5):332–335. doi:10.1038/sj.sc.3100814

17. American Society of Anesthesiologists Task Force on Perioperative Blood Management. "Practice guidelines for perioperative blood management." Anesthesiology. 2015;122(2):241–275. doi:10.1097/ALN.0000000000000463

18. Te AE, Te AG, Ramaswamy A, Kaplan SA. "Practical management of hematuria after endoscopic surgery for benign prostatic obstruction." Prostate Cancer Prostatic Dis. 2026. doi:10.1038/s41391-026-01111-w

19. Angelousi A, Alexandraki KI, Mytareli C, Grossman AB, Kaltsas G. "New developments and concepts in the diagnosis and management of diabetes insipidus (AVP-deficiency and resistance)." J Neuroendocrinol. 2023;35(1):e13233. doi:10.1111/jne.13233

20. Tomkins M, Lawless S, Martin-Grace J, Sherlock M, Thompson CJ. "Diagnosis and management of central diabetes insipidus in adults." J Clin Endocrinol Metab. 2022;107(10):2701–2715. doi:10.1210/clinem/dgac381

21. Fralick M, Schneeweiss S, Wallis CJD, Jung EH, Kesselheim AS. "Desmopressin and the risk of hyponatremia: a population-based cohort study." PLoS Med. 2019;16(10):e1002930. doi:10.1371/journal.pmed.1002930

22. Chin X, Teo SW, Lim ST, et al. "Desmopressin therapy in children and adults: pharmacological considerations and clinical implications." Eur J Clin Pharmacol. 2022;78(6):907–917. doi:10.1007/s00228-022-03297-z